Apr 26, 2025

Featuring perspectives from Ms Marianne J Davies, Dr Edward B Garon, Ms Marissa Marti-Smith and Dr Tiffany A Traina, including the following topics:

• Introduction (0:00)
• Overview of Antibody-Drug Conjugates (ADCs) (4:40)
• Trastuzumab Deruxtecan (T-DXd) in Patients with HER2-Positive Metastatic Breast Cancer (mBC) with...

Mar 29, 2025

Featuring an interview with Dr Christopher L Moertel, including the following topics:

• Overview of neurofibromatosis type 1(NF1) (0:00)
• Cancer in NF1 (8:38)
• Dermatologic manifestations of NF1 (16:57)
• Treatment options for NF1 (20:43)
• Malignant peripheral nerve sheath tumors (MPNST) (25:14)
• FDA-approved MEK inhibitors...

Mar 28, 2025

Featuring a slide presentation and related discussion from Dr Christopher L Moertel, including the following topics:

• Overview of neurofibromatosis (0:00)
• Common clinical manifestations of neurofibromatosis type 1 (NF1) (14:13)
• Role of MEK inhibitors in the management of NF1 plexiform neurofibromas (29:30)

Jun 21, 2023

Featuring perspectives from Dr Lyudmila A Bazhenova, Ms Kelly EH Goodwin, Dr Virginia Kaklamani, Ms Caroline Kuhlman, Ms Alexis N McKinney and Dr Zev Wainberg, including the following topics:

• Introduction (0:00)
• HER2 as a Therapeutic Target; Antibody-Drug Conjugates (6:15)
• HER2-Positive Breast Cancer (23:08)

Feb 28, 2023

Featuring a slide presentation and related discussion from Dr Mrinal Gounder, including the following topics:

•      Efficacy and tolerability of sorafenib in patients with advanced and refractory desmoid tumors (00:00)

•      DESMOPAZ: Results of a Phase II trial of pazopanib versus IV methotrexate/vinblastine...